These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37296589)

  • 21. Imaging of Reactive Astrogliosis by Positron Emission Tomography.
    Harada R; Furumoto S; Kudo Y; Yanai K; Villemagne VL; Okamura N
    Front Neurosci; 2022; 16():807435. PubMed ID: 35210989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's disease.
    Ferrari-Souza JP; Ferreira PCL; Bellaver B; Tissot C; Wang YT; Leffa DT; Brum WS; Benedet AL; Ashton NJ; De Bastiani MA; Rocha A; Therriault J; Lussier FZ; Chamoun M; Servaes S; Bezgin G; Kang MS; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Klunk WE; Tudorascu DL; Cohen AD; Villemagne VL; Gauthier S; Blennow K; Zetterberg H; Souza DO; Karikari TK; Zimmer ER; Rosa-Neto P; Pascoal TA
    Mol Psychiatry; 2022 Nov; 27(11):4781-4789. PubMed ID: 35948658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies.
    Ji B; Maeda J; Sawada M; Ono M; Okauchi T; Inaji M; Zhang MR; Suzuki K; Ando K; Staufenbiel M; Trojanowski JQ; Lee VM; Higuchi M; Suhara T
    J Neurosci; 2008 Nov; 28(47):12255-67. PubMed ID: 19020019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease.
    Fontana IC; Kumar A; Nordberg A
    Nat Rev Neurol; 2023 May; 19(5):278-288. PubMed ID: 36977843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Key Mediator and Imaging Target in Alzheimer's Disease: Unlocking the Role of Reactive Astrogliosis Through MAOB.
    Nam MH; Na H; Justin Lee C; Yun M
    Nucl Med Mol Imaging; 2024 Jun; 58(4):177-184. PubMed ID: 38932762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease.
    Carter SF; Chiotis K; Nordberg A; Rodriguez-Vieitez E
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):348-356. PubMed ID: 30515545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography.
    Schöll M; Carter SF; Westman E; Rodriguez-Vieitez E; Almkvist O; Thordardottir S; Wall A; Graff C; Långström B; Nordberg A
    Sci Rep; 2015 Nov; 5():16404. PubMed ID: 26553227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings.
    Hall B; Mak E; Cervenka S; Aigbirhio FI; Rowe JB; O'Brien JT
    Ageing Res Rev; 2017 Jul; 36():50-63. PubMed ID: 28315409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring.
    van Oostveen WM; de Lange ECM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.
    Cohen AD; Landau SM; Snitz BE; Klunk WE; Blennow K; Zetterberg H
    Mol Cell Neurosci; 2019 Jun; 97():3-17. PubMed ID: 30537535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
    Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
    JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlations of
    Harada R; Ishiki A; Kai H; Sato N; Furukawa K; Furumoto S; Tago T; Tomita N; Watanuki S; Hiraoka K; Ishikawa Y; Funaki Y; Nakamura T; Yoshikawa T; Iwata R; Tashiro M; Sasano H; Kitamoto T; Yanai K; Arai H; Kudo Y; Okamura N
    J Nucl Med; 2018 Apr; 59(4):671-674. PubMed ID: 28864633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dynamics of plasma biomarkers across the Alzheimer's continuum.
    Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
    Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque.
    Holland JP; Liang SH; Rotstein BH; Collier TL; Stephenson NA; Greguric I; Vasdev N
    J Labelled Comp Radiopharm; 2014 Apr; 57(4):323-31. PubMed ID: 24327420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
    Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preclinical and clinical study on [
    Xu M; Guo J; Gu J; Zhang L; Liu Z; Ding L; Fu H; Ma Y; Liang S; Wang H
    Eur J Nucl Med Mol Imaging; 2022 Jan; 49(2):652-663. PubMed ID: 34292345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography.
    Tripathi SM; Murray AD
    Neuroscientist; 2022 Oct; 28(5):507-519. PubMed ID: 33660556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.